Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04365660 · ClinicalTrials.gov registry record · Phase 2
18F-FTC-146 PET/CT in Newly-Diagnosed Osteosarcoma
A Phase 2 study, sponsored by Davidzon, Guido, M.D..
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT04365660 is a Phase 2 study that was terminated before completion, run by Davidzon, Guido, M.D.. The registered enrollment target is 1 participants.
The verdict
NCT04365660, a Phase 2 study, was terminated before completion, sponsored by Davidzon, Guido, M.D..
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
The purpose of this research is to evaluate the study drug, 18F FTC-146, as a positron emission tomography (PET) / computed tomography (CT) radiotracer imaging agent to evaluate tumor status in patients newly diagnosed with osteosarcoma ("bone cancer").
Interventions
- DRUG 18-F FTC 146
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2021-01-28 |
| Est. Completion | 2021-07-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04365660
The ClinicalTrials.gov registry entry for NCT04365660 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Davidzon, Guido, M.D., which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 18-F FTC 146 is the first listed.
NCT04365660 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04365660 about?
NCT04365660 is a clinical study titled "18F-FTC-146 PET/CT in Newly-Diagnosed Osteosarcoma". The purpose of this research is to evaluate the study drug, 18F FTC-146, as a positron emission tomography (PET) / computed tomography (CT) radiotracer imaging agent to evaluate tumor status in patients newly diagnosed with osteosarcoma ("bone cancer").
What is the current status of trial NCT04365660?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2021-01-28. Estimated completion is 2021-07-22.
What interventions are being tested in trial NCT04365660?
The interventions under investigation include: 18-F FTC 146 (DRUG).
Who is sponsoring clinical trial NCT04365660?
This trial is sponsored by Davidzon, Guido, M.D., which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.